When analysing the prognostic impact of BAF/PBAF mutations according to tumor mutational burden (TMB) level, BAF/PBAF mutations were associated with overall survival only in tumors with low TMB (< 10 mutations/megabase) (21 months versus 14 months, p = 0.024) (Fig. 1c-d) who represented the majority of patients (n = 1173, 70.6%). The gene discussed is BANF1; the disease is neoplasm.